Basel, January 16, 2026 – Novartis today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation…
Basel, January 9, 2026 – Novartis, a leading global innovative medicines company, today announced plans to build its fourth US…
The first Temerario delivered in the Americas highlights the extensive personalization possibilities of Lamborghini’s Ad Personam programSant’Agata Bolognese/Miami, FL December…
Positive results from ianalumab pivotal Phase III trial in ITP patients previously treated with corticosteroids to be presented as late-breakerScemblix…
– Strategic investment enhances service to North American customers and supports rising market demand for high-quality ingredients – BASEL, Switzerland,…
- New research confirms Jungbunzlauer's TCC TB supports efficient, high-quality tablet manufacturing across challenging pharmaceutical and nutraceutical applications - BASEL,…
Basel, October 19, 2025 – Novartis today presents new Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan) data from the Phase III PSMAddition…
Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving UME and may offer a potential new treatment…
PARIS, Oct. 7, 2025 /PRNewswire/ -- With Frieze London about to kick off, followed by Art Basel Paris, Artprice News®…
– establishing U.S. manufacturing footprint – BASEL, Switzerland, Sept. 2, 2025 /PRNewswire/ -- Jungbunzlauer, a global leader in high-quality, sustainable…